Related Experiment Video

Updated: Aug 7, 2026

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

Ventricular remodeling in heart failure and the effect of beta-blockade

James E Udelson1

  • 1Division of Cardiology, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA. JUdelson@tufts-nemc.org

The American Journal of Cardiology
|May 18, 2004
PubMed

Insights

Understanding left ventricular (LV) remodeling is key to treating heart failure. Beta-blockers, especially carvedilol, combined with ACE inhibitors, offer the best outcomes for reducing mortality and improving LV remodeling.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Research

Background:

  • Left ventricular (LV) remodeling significantly contributes to cardiovascular disease progression.
  • Understanding LV remodeling enhances knowledge of heart failure pathophysiology.
  • Drug therapies targeting remodeling show favorable effects on disease progression.

Purpose of the Study:

  • To review the role of drug therapies in modifying left ventricular remodeling.
  • To compare the effects of Angiotensin-converting enzyme (ACE) inhibitors and beta-blockers on LV remodeling and patient outcomes.
  • To investigate potential differences among beta-blockers in their impact on remodeling.

Main Methods:

  • Review of existing studies and meta-analyses on LV remodeling.
  • Analysis of data on drug therapies, including ACE inhibitors and beta-blockers.
  • Comparison of therapeutic effects on mortality and reverse remodeling.

Main Results:

  • ACE inhibitors significantly reduce mortality.
  • Beta-blockers provide independent benefits on post-myocardial infarction remodeling.
  • Combination therapy with ACE inhibitors and beta-blockers yields the greatest mortality reduction and reverse remodeling.
  • Carvedilol demonstrates a potentially superior effect on LV remodeling compared to other beta-blockers.

Conclusions:

  • Drug therapies targeting LV remodeling are crucial for managing heart failure.
  • Combination therapy with ACE inhibitors and beta-blockers is most effective.
  • Carvedilol may offer the most favorable impact on LV remodeling and patient outcomes.

More Related Videos

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...